Christian Angermayer is a German entrepreneur and founder of Apeiron Investment Group, a family office that invests across life sciences, fintech, artificial intelligence, psychedelics, cryptocurrencies and longevity research. This page tracks the publicly traded companies and digital assets in which Angermayer holds ownership positions through his investment vehicles.
Compass Pathways pioneers evidence-based mental health innovations, developing psilocybin therapies for treatment-resistant depression and other serious conditions.
AtaiBeckley develops and advances clinical-stage psychedelic-based and neuropharmacology therapies for mental health conditions, including treatment-resistant depression.
Bionomics develops novel ion channel modulators for treating serious central nervous system disorders like anxiety and PTSD.
AbCellera is a biotechnology company specializing in antibody discovery and development, partnering with leading pharmaceutical firms to create innovative therapies.
Super Copper explores high-grade copper in Chile's Atacama, combining advanced mining with sustainable biopolymer tech for efficient, eco-friendly extraction.
Bitcoin (BTC) is the original cryptocurrency, introduced in 2008 in a whitepaper published under the pseudonym Satoshi Nakamoto. The network operates as a peer-to-peer electronic c
Christian Angermayer founded Apeiron Investment Group, a family office with a concentrated focus on sectors at the intersection of science, technology and finance. His investment philosophy centers on identifying scientific and technological shifts with the capacity to reshape industries, with particular emphasis on areas that remain underexplored by traditional capital markets.
Apeiron's portfolio spans life sciences, psychedelic medicine, artificial intelligence, blockchain, digital assets, fintech and longevity research. Angermayer is a prominent advocate for psychedelic-assisted therapies as a treatment for mental health conditions, backing companies developing clinical applications for substances like psilocybin and MDMA. His investment approach combines scientific due diligence with a willingness to enter markets before they reach broad institutional awareness.
Beyond psychedelics, Angermayer's interests extend to biotechnology companies working on age-related diseases, cryptocurrency infrastructure and AI-powered platforms. Tracking his publicly disclosed positions offers a view into sectors where scientific research and commercial application intersect, particularly in areas where regulatory frameworks and clinical validation pathways remain complex and evolving.
The companies and digital assets featured on this page represent Angermayer's publicly held positions across multiple jurisdictions and stages of development. His portfolio reflects a thematic investing approach that targets the convergence of scientific research, regulatory evolution and market formation across healthcare, financial technology and digital asset sectors.
Join top talent at the world's most respected institutions, companies, and venture capital funds.
